Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamidronate for thalassemia-induced osteoporosis
IRCT20211008052698N1Phase 2Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamidronate in osteoporosis and beta thalassemia, sponsored by Urmia University of Medical Sciences. Primary endpoint: Bone mineral densitometry. Started Sep 2020; status: completed.
02
Drugs
pamidronate
03
Conditions
osteoporosisbeta thalassemia
Beyond the preview
Go deeper on IRCT20211008052698N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211008052698N1.